Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use KOVALTRY safely and effectively. See full prescribing information for KOVALTRY.KOVALTRY [Antihemophilic Factor (Recombinant)]Lyophilized Powder for Solution for Intravenous Injection – Reconstitution with Vial AdapterInitial U.S. Approval: 2016
Medication labelWhy this: Advisory · dailymed-other
KOVALTRY, Antihemophilic Factor (Recombinant), is a recombinant, human DNA sequence derived, full length Factor VIII concentrate indicated for use in adults and children with hemophilia A (congenital Factor VIII deficiency) for: •On-demand treatment and control of bleeding episodes •Perioperative management of bleeding •Routine prophylaxis to reduce the frequency of bleeding episodes KOVALTRY is not indicated for the treatment of von Willebrand disease.
- generic_name
- antihemophilic factor (recombinant)
- brand_name
- water, Antihemphilic Factor (Recombinant)
- product_names
- Antihemophilic Factor (Recombinant), water, Antihemphilic Factor (Recombinant)
- ndc
- 0026-3821, 0026-3821-25, 0026-3821-99, 0026-4821, 0026-4821-01, 0026-4821-99, 0026-0426, 0026-0426-02, 0026-3822, 0026-3822-25, 0026-3822-99, 0026-4822, 0026-4822-01, 0026-4822-99, 0026-3824, 0026-3824-25, 0026-3824-99, 0026-4824, 0026-4824-01, 0026-4824-99, 0026-3826, 0026-3826-50, 0026-3826-99, 0026-4826, 0026-4826-01, 0026-4826-99, 0026-0426-05, 0026-0426-15, 0026-3828, 0026-3828-50, 0026-3828-99, 0026-4828, 0026-4828-01, 0026-4828-99
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en